Contact
QR code for the current URL

Press release Box-ID: 214563

Capsulution Pharma AG Volmerstr. 7b 12489 Berlin, Germany http://www.capsulution.com/
Contact Mr Dr. Joachim Bender +49 30 6706919122
Company logo of Capsulution Pharma AG
Capsulution Pharma AG

Capsulution and NanoDel merge their businesses

Capsulution Pharma AG combines modern Drug delivery technologies for crossing the blood brain barrier

(PresseBox) (Berlin/Magdeburg, )
The combination of the Berlin based drug delivery company Capsulution Nanoscience AG and the Magdeburg based biopharmaceutical company NanoDel Technologies GmbH under the name Capsulution Pharma AG creates a top-class company in the field of nanoparticle based drug delivery and drug development. Capsulution Pharma will use its proprietary drug delivery technologies for own drug developments preferably in the indication fields of the central nervous system (CNS) and cancer related diseases. In addition, Capsulution Pharma is continuing to use its technologies for life cycle management of already marketed products in collaboration with external drug developers. The merger took place by a share exchange and was accompanied by an internal investment round of ¤ 2.5 million (IBG RKF I, B. Penno, Quercus GmbH, BC Brandenburg Capital GmbH over the fonds KBB and founders).

Capsulution Pharma's first product, Doxorubicin loaded into nanoparticles, is in preclinical stage to treat devastating primary and secondary brain tumors. Up to now broadly used cytostatic Doxorubicin formulations are inactive in these CNS related indications due to the lack of penetrating the so called blood brain barrier. The biologically degradable PBCA nanoparticles (Poly-Butyl-Cyano-Acrylate) originally developed by NanoDel have specifically the ability to transport pharmaceutical drugs across the blood brain barrier into brain tissue. Doxorubicin-nanoparticles already tested successfully in mice and rats are expected to enter phase Ia/IIb trials with glioma patients in second half of 2009. If the very promising preclinical data can be confirmed in humans, the technology could initiate a therapeutic breakthrough for the treatment of brain cancer as well as other brain related diseases with high unmet medical needs, e.g. pain, migraine, depression and Alzheimer's.

"In addition, the combination of the innovative drug delivery technologies of both partners opens new possibilities for drug application routes which are very difficult to achieve with today's existing delivery systems," explains Dr. Voigt, the company's CSO. "Furthermore, oral protein application and specific tissue targeting of therapeutics to increase their efficacy and to reduce unwanted side effects, are other exciting options," adds CTO, Prof. Radunz, the former head of pre-clinical research at Merck KGaA.

"Using novel drug delivery technologies and applying them to already marketed products with poor local CNS bioavailability for own drug development reduces development risk, costs and time to market significantly compared to the development of new chemical entities," declares Dr. Joe Bender (ex Bayer), the company's new CEO. "With its dual business strategy, product development and live cycle management, Capsulution Pharma will both participate in the value chain of pharmaceutical drug development and explore the full potential of its innovative drug delivery systems in collaboration with out-side partners." In this respect, polyelectrolyte based nanoparticle encapsulation (Layer by Layer, Polyelectrolyte Complex) is used to formulate poorly water soluble and/or instable pharmaceuticals for external customers.

Prof. Dr. Dieter Berg, chairman of the supervisory board, underlines that the unique combination of the nanoparticle based technologies from both partners and the attractive development product make Capsulution Pharma a very interesting partner both for pharma and biotech companies as well as for investors who want to participate in the Company's growth potential.

Capsulution Pharma AG

About Capsulution NanoScience AG
Capsulution NanoScience AG, founded in 2000 as a spin-off of the Max-Planck Institute of Colloids and Interfaces in Golm, Germany, is a leading nanotechnology company focusing on the development of innovative drug delivery systems. These polyelectrolyte based technologies (Layer by Layer, Polyelectrolyte Complex) are high-tech tools for the production of multi-functional nanocapsules. They provide novel tailor made (lego-like) drug delivery solutions to improve drug efficacy and to reduce unwanted side effects. Due to their minuscule size, high payload, numerous options to take on a variety of functions, and high reproducibility such nanocapsules can be used effectively in a wide range of life-science applications.

About NanoDel Technologies GmbH:
NanoDel Technologies GmbH was established in Magdeburg in late 2003. NanoDel's basic technology originally developed by Prof. Kreuter, University Frankfurt, was turned into a manufacturable and scalable drug delivery system to transport pharmaceutical compounds (e.g. Doxorubicin) preferably across the blood brain barrier into brain tissue. The blood brain barrier physiologically prevents - like a fire wall - more than 95% of all drugs to enter the brain and, therefore, limits the pharmaceutical efficacy of potentially lifesaving CNS pharmaceuticals.

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2022, All rights reserved

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.